Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A6 in persistent or recurrent ovarian cancer
NCT00939809Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Jul 2009
- Primary completion
- Jul 2012
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bifidobacterium animalis lactis in ovarian epithelial carcinoma, fallopian tube carcinoma (PFTC) and primary peritoneal carcinoma (PPC), sponsored by GOG Foundation. Primary endpoints: Progression-free Survival at 6 Months, Objective Tumor Response Rate up to 5 years and 1 more. Started Jul 2009; status: completed.
02
Drugs
bifidobacterium animalis lactis
03
Conditions
ovarian epithelial carcinomafallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00939809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00939809.